NASDAQ:IBRX - ImmunityBio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.00
  • Forecasted Upside: 47.41 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$16.96
▼ -0.42 (-2.42%)
1 month | 3 months | 12 months
Get New ImmunityBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IBRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IBRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$25.00
▲ +47.41% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ImmunityBio in the last 3 months. The average price target is $25.00, with a high forecast of $25.00 and a low forecast of $25.00. The average price target represents a 47.41% upside from the last price of $16.96.
Buy
The current consensus among 1 contributing investment analysts is to buy stock in ImmunityBio.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/7/2021Piper SandlerBoost Price TargetOverweight$18.00 ➝ $25.00Medium
i
(Data available from 4/19/2016 forward)
ImmunityBio logo
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy. It develops an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors, macrophage polarizing peptides, bi-specific fusion proteins targeting TGFb and IL-12, adenovirus, and yeast vaccine therapies targeting tumor-associated antigens and neoepitopes. ImmunityBio, Inc. was formerly known as NantCell, Inc. and changed its name to ImmunityBio, Inc. in June 2019. The company was incorporated in 2014 and is based in El Segundo, California. ImmunityBio, Inc. operates as a subsidiary of NantWorks, LLC.
Read More

Today's Range

Now: $16.96
$16.80
$17.83

50 Day Range

MA: N/A

52 Week Range

Now: $16.96
$3.16
$45.42

Volume

693,153 shs

Average Volume

1,493,142 shs

Market Capitalization

$1.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ImmunityBio?

The following Wall Street sell-side analysts have issued reports on ImmunityBio in the last twelve months: Piper Sandler.
View the latest analyst ratings for IBRX.

What is the current price target for ImmunityBio?

1 Wall Street analysts have set twelve-month price targets for ImmunityBio in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 47.4%. Piper Sandler has the highest price target set, predicting IBRX will reach $25.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $25.00 for ImmunityBio in the next year.
View the latest price targets for IBRX.

What is the current consensus analyst rating for ImmunityBio?

ImmunityBio currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IBRX will outperform the market and that investors should add to their positions of ImmunityBio.
View the latest ratings for IBRX.

What other companies compete with ImmunityBio?

How do I contact ImmunityBio's investor relations team?

The company's listed phone number is 310 883 1300. The official website for ImmunityBio is immunitybio.com.